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constraints were violated we re-checked correspondence of 
the structures to the delineation standards of the Lungtech 
protocol. Association of violations and the prospectively 
recorded toxicity was evaluated. 
 
Results: According to DVHs 111 SBRT plans did not violate 
any of the dose constraints requested in the Lungtech trial. 
For 7/100 patients SBRT plans exceeded the Lungtech dose 
constraint for the proximal bronchial tree of EqD2=74.8Gy to 
> 0.5cc, one of them additionally for the esophagus of 
EqD2=64 Gy. 6/7 patients showed an increase in dyspnea, 2 
of them died 3 and 9 months after SBRT, one after 
hemoptysis and subsequent pneumonia, the other after being 
hospitalized for unclear progressive dyspnea; in both cases 
association of G5 toxicity to SBRT cannot be excluded. 
 
Conclusion: Despite the lack of detailed specific constraints 
within the STRIPE trial OAR exposure did not largely differ 
from current practice in modern SBRT. However, these 
preliminary results underline the importance of the dose 
constraints for the main airways within the Lungtech trial and 
the necessity to continuously review and adjust treatment 
procedures to upcoming evidence, especially when employing 
new techniques. 
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Purpose or Objective: SABR for primary NSCLC is becoming 
increasingly popular as evidence is mounting for its 
equivalent long-term clinical outcomes and good overall 
tolerability. We review our toxicity against dosimetry and 
achievement of dose constraints (SABR UK Consortium). We 
suggest that dosimetric constraints alone cannot be used to 
prevent SABR related side effects. 
 
Material and Methods: Patients with stage I NSCLC treated 
with SABR between January 2014 and August 2015 were 
included in this single centre cohort study. They were 
planned using relaxed breathing 4D CT then treated using 
VMAT. Baseline and dosimetric data was retrospectively 
collected by a clinical oncologist or physicist from the 
radiotherapy records. Patients were followed up at 4 weeks 
then at 3 monthly intervals until 1 year. CT scans were 
performed 3 and 12 months post radiotherapy. Prospective 
data collection was performed at follow up visits for clinical 
outcomes and acute and late normal tissue toxicity (scored 
using CTCAE v 3.0). 
 
Results: 28 patients were included in the study with a 
median follow up of 10.4 months. 19 patients have attended 
for post radiotherapy CT scans with 84.2% showing 
radiological response as per RECIST. All patients were 
assessed for acute toxicity data, 3.5% (1/28) noted grade 2 
reaction. Data on late toxicity was available for 19 patients: 
26.3% (5/19) experienced grade 2-3, no grade 4 or 5 reactions 
were recorded. When adjusted for baseline function (late 
toxicity score minus baseline score) this fell to 15% (3/19). 
Other than chest wall (CW) tolerances all dosimetry criteria 
were met. 10.7% of plans exceeded tolerance to 30cc CW 
(>30/32) with no recorded episodes of ≥grade 2 CW pain in 
these patients. 71.4% of plans exceeded dose constraint to 
0.01cc CW (>37/39) only 5% (1/20) complained of CW pain. 
Dosimetric analysis for this patient revealed dose to 30cc of 
CW was 25.8 Gy (<32), dose to 0.01 cc of CW was 59.1 Gy 
(<39), volume of PTV and CW overlapping was 0.03 cc and % 
of PTV-CW overlapping was 0.21%. 
 
Conclusion: We are achieving low rates of moderate or 
severe toxicity. Despite achieving dose constraints, a small 
cohort of patients developed toxicity grade 2-3. We 
hypothesize that these patients could develop radiotherapy 
toxicity due to other idiosyncratic factors (genetic 
polymorphisms, microenvironment). Further studies are 
currently running to investigate other causative factors. 
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Purpose or Objective: The aim of this study is to evaluate 
efficacy and toxicity of stereotactic body radiation therapy in 
early stage medically inoperable non-small lung cancer. 
 
Material and Methods: Data from patients affected by 
medically inoperable stage I NSCLC treated with stereotactic 
body radiation therapy (SBRT) were prospectively recorded. 
Treatments were planned employing 4D-CT . The prescribed 
dose was modulated according to location of the lesion and 
tolerance of the surrounding organs at risk: 54 Gy in 3 
fractions for peripheral lesions, 60 Gy in 4 fractions for 
lesions adjacent to the chest wall, 60 Gy in 8 fractions for 
central lesions. The primary endpoints were local control and 
toxicity, secondary endpoint was survival. The follow-up 
examinations were performed with CT and/or PET-CT at 1, 3, 
6, 9 and 12 months after treatment and every 6 months 
subsequentely. Acute and late side effects were recorded 
according to RTOG morbidity Scoring Scale.  
 
Results: From 2009 to 2014, 65 patients were treated. Mean 
patients’ age was 74 years (range 62-86). The lesions had a 
mean maximum diameter of 20 mm (range 10-36). All but 
seven patients were staged by PET-CT. 83% of cases lung 
cancer was histologically proven: 34 cases were 
adenocarcinoma, 15 squamous cell carcinomas, 5 
undifferentiated carcinomas. In the last 11 patients biopsy 
was not performed because of high risk features for 
complications and/or patient’s refusal. In this last group 81% 
had a positive PET-CT and lesion growth documented at 
subsequent CT and just two patients had only lesion growth. 
Lesion’s location were as follow: RUL 25/65 (38%), RML 2/65 
(3%), RIL 7/65 (11%), LUL 22/65 (34%) and LIL 9/65 (14%). 
Median follow-up in 61 evaluable patients was 40 months. 
Five local failure (8%) were recorded at a mean of 11,5 
months from the end of treatment (range 5.3-22). PET-CT 
SUV was the only parameter predictive for local failure, with 
a mean value of 14,2 in the recurrence group versus 6,1 in 
the recurrence-free group, respectively; p=0.03. Local 
control at 1 and 2 years were 89.6% and 86%. Median DFS was 
22.2 months and 1y-, 2y- and 3y- DFS were 66%, 47% and 40%, 
respectively. Lesions’ location according to treatment group 
was related to distant progression, which was significantly 
higher in peripheral location (p=0.004). Overall survival at 1y-
, 2y- and 3y were 97%, 77% and 66%, respectively. Treatment 
was well tolerated. G1 asymptomatic pulmonary toxicity was 
observed in 18% of cases (11/61), G2 pulmonary toxicity was 
recorded in 3% of patients. There were no pulmonary toxicity 
grade 3-4. No other toxicities were reported. 
 
Conclusion: SBRT is an effective and safe treatment for 
patients with medically inoperable stage I NSCLC. Local 
recurrence predictive value of PET-CT SUV could be 
investigated in bigger series. 
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Purpose or Objective: Radiation therapy in the palliation of 
intra-thoracic symptoms from locally advanced non-small cell 
lung cancer (NSCLC) is a significant component of workload in 
most radiotherapy departments. While most trials have 
